Anthony Johnson

Biography

Anthony Johnson is Vice President, Early Clinical Development at AstraZeneca’s world-leading IMED Biotech Unit. Anthony joined AstraZeneca in 2014, holding a wealth of experience in exploratory clinical development across the pharmaceutical industry and academia. In his role he has recruited world- leading MD.PhDs and significantly improved both translational clinical science and operations, such as clinical trial cycle times. He oversees the iDecide program including REACT which focuses on real time visualisation and analysis of clinical trial data, while incorporating patient perspectives. REACT allows AstraZeneca to improve clinical trial design and ultimately enables patients to receive medicines more quickly. Anthony is a Fellow at Homerton College, University of Cambridge and, prior to AstraZeneca, was a Board Director for Cardioxyl (2012-2015) and Rgenix (2014-2015), and a Venture Partner at OrbiMed Advisors, a global healthcare-only investment firm (2012-2013). Preceding his life sciences investment experience, he led exploratory clinical development as Vice President, Discovery Medicine Clinical Pharmacology at Bristol-Myers Squibb (2006-2012) and served as Vice President on the executive team of the Center of Excellence for Drug Discovery responsible for multiple therapeutic areas at GlaxoSmithKline (2001-2006). Complementing his substantial healthcare industry leadership experience, Dr. Johnson has 18 years of broad clinical practice experience. In addition, Dr. Johnson has published extensively in and served as an external reviewer for several international, peer reviewed journals, has attracted national peer-reviewed research grant funding in multiple countries and has broad teaching experience including invited presentations at numerous scientific and medical meetings.

Research Interest

clinical development